Travere Therapeutics: Specialist in Kidney Therapies Increases FILSPARI Revenue by 88%!
Reading Time: 3 minutes
Travere Therapeutics secures an important FDA approval expansion for its main product FILSPARI in April for the treatment of FSGS. FILSPARI could generate peak sales of $3 billion in the long term and reach around 300,000 patients in the U.S. In the first quarter, FILSPARI grew by 88% in a record quarter as the most prescribed IgAN therapy. Travere Therapeutics (TVTX) has specialized as a biopharmaceutical company in providing therapies for rare diseases. The current business model with the main product FILSPARI (Sparsentan) is heavily...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
